These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 29300958)

  • 1. Sweet SIGNs: IgG glycosylation leads the way in IVIG-mediated resolution of inflammation.
    Brückner C; Lehmann C; Dudziak D; Nimmerjahn F
    Int Immunol; 2017 Dec; 29(11):499-509. PubMed ID: 29300958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous immunoglobulin therapy: how does IgG modulate the immune system?
    Schwab I; Nimmerjahn F
    Nat Rev Immunol; 2013 Mar; 13(3):176-89. PubMed ID: 23411799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IVIG-mediated effector functions in autoimmune and inflammatory diseases.
    Galeotti C; Kaveri SV; Bayry J
    Int Immunol; 2017 Dec; 29(11):491-498. PubMed ID: 28666326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 7th International Immunoglobulin Conference: Mechanisms of action.
    Basta M; Branch DR
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):111. PubMed ID: 25546783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The other side of immunoglobulin G: suppressor of inflammation.
    Aschermann S; Lux A; Baerenwaldt A; Biburger M; Nimmerjahn F
    Clin Exp Immunol; 2010 May; 160(2):161-7. PubMed ID: 20041883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs.
    Anthony RM; Ravetch JV
    J Clin Immunol; 2010 May; 30 Suppl 1():S9-14. PubMed ID: 20480216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective.
    Sibéril S; Elluru S; Graff-Dubois S; Negi VS; Delignat S; Mouthon L; Lacroix-Desmazes S; Kazatchkine MD; Bayry J; Kaveri SV
    Ann N Y Acad Sci; 2007 Sep; 1110():497-506. PubMed ID: 17911465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a receptor required for the anti-inflammatory activity of IVIG.
    Anthony RM; Wermeling F; Karlsson MC; Ravetch JV
    Proc Natl Acad Sci U S A; 2008 Dec; 105(50):19571-8. PubMed ID: 19036920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DC-SIGN and alpha2,6-sialylated IgG Fc interaction is dispensable for the anti-inflammatory activity of IVIg on human dendritic cells.
    Bayry J; Bansal K; Kazatchkine MD; Kaveri SV
    Proc Natl Acad Sci U S A; 2009 Mar; 106(9):E24; author reply E25. PubMed ID: 19237553
    [No Abstract]   [Full Text] [Related]  

  • 10. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway.
    Anthony RM; Kobayashi T; Wermeling F; Ravetch JV
    Nature; 2011 Jun; 475(7354):110-3. PubMed ID: 21685887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous immunoglobulin (IVIg) in the treatment of autoimmune and inflammatory diseases.
    Ruiz de Souza V; Kaveri SV; Kazatchkine MD
    Clin Exp Rheumatol; 1993; 11 Suppl 9():S33-6. PubMed ID: 8354005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Normal polyspecific immunoglobulin G (IVIg) in the treatment of autoimmune diseases.
    Hurez V; Kaveri SV; Kazatchkine MD
    J Autoimmun; 1993 Dec; 6(6):675-81. PubMed ID: 8155249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissecting the molecular mechanism of IVIg therapy: the interaction between serum IgG and DC-SIGN is independent of antibody glycoform or Fc domain.
    Yu X; Vasiljevic S; Mitchell DA; Crispin M; Scanlan CN
    J Mol Biol; 2013 Apr; 425(8):1253-8. PubMed ID: 23416198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissecting the mechanism of action of intravenous immunoglobulin in human autoimmune disease: Lessons from therapeutic modalities targeting Fcγ receptors.
    Shock A; Humphreys D; Nimmerjahn F
    J Allergy Clin Immunol; 2020 Sep; 146(3):492-500. PubMed ID: 32721416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation.
    Kaneko Y; Nimmerjahn F; Ravetch JV
    Science; 2006 Aug; 313(5787):670-3. PubMed ID: 16888140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 7th International Immunoglobulin Conference: Mechanisms of action.
    Basta M; Branch DR
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):87-8. PubMed ID: 25546774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs.
    Fiebiger BM; Maamary J; Pincetic A; Ravetch JV
    Proc Natl Acad Sci U S A; 2015 May; 112(18):E2385-94. PubMed ID: 25870292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IgG Fc N-glycosylation in Guillain-Barré syndrome treated with immunoglobulins.
    Fokkink WJ; Selman MH; Dortland JR; Durmuş B; Kuitwaard K; Huizinga R; van Rijs W; Tio-Gillen AP; van Doorn PA; Deelder AM; Wuhrer M; Jacobs BC
    J Proteome Res; 2014 Mar; 13(3):1722-30. PubMed ID: 24533874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulating effects of intravenous immunoglobulin in autoimmune and inflammatory diseases.
    Kaveri SV; Mouthon L; Kazatchkine MD
    J Neurol Neurosurg Psychiatry; 1994 Nov; 57 Suppl(Suppl):6-8. PubMed ID: 7964857
    [No Abstract]   [Full Text] [Related]  

  • 20. New insights into IVIg mechanisms and alternatives in autoimmune and inflammatory diseases.
    Norris PAA; Kaur G; Lazarus AH
    Curr Opin Hematol; 2020 Nov; 27(6):392-398. PubMed ID: 32868670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.